Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Advances in Cell Signaling Pathways: A Comprehensive Review

Journal of Cellular Biology·2024

Same author

Novel Approaches to Tissue Engineering and Regenerative Medicine

Nature Methods·2023

Same author

Understanding Molecular Mechanisms in Disease Progression

Cell Reports·2023

Same author

Genomic Profiling Reveals New Biomarkers for Early Diagnosis

Nature Genetics·2023

Same author

CRISPR-Based Screening Identifies Key Regulators of Cell Growth

Cell Reports·2022

Same author

Structural Insights into Membrane Protein Function

Journal of Cellular Biology·2022

Search research articles

Related Experiment Video

Updated: Jan 8, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

SDCBP2 promotes tumor progression and is a novel ferroptosis-related prognostic biomarker in lung adenocarcinoma.

Shaowu Sun^1,2,3,4,5, Zhuoyu Gu^2,4,5, Shuang Yuan^2,4,5

¹State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.

Frontiers in Immunology

|December 18, 2025

Summary

This study identifies SDCBP2 as a key factor in lung adenocarcinoma (LUAD) progression. Targeting SDCBP2 may offer new therapeutic strategies and improve prognosis for LUAD patients by influencing ferroptosis.

Keywords:

SDCBP2 apoptosis cell cycle ferroptosis lung adenocarcinoma prognostic marker

More Related Videos

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

Related Experiment Videos

Last Updated: Jan 8, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

Area of Science:

Oncology
Molecular Biology
Biochemistry

Background:

Lung adenocarcinoma (LUAD) presents a significant global health challenge due to its aggressive nature and poor patient outcomes.
Ferroptosis, a regulated form of cell death, is implicated in LUAD progression, yet critical ferroptosis-related factors remain underexplored.
Identifying novel therapeutic targets and prognostic biomarkers is crucial for improving LUAD management.

Purpose of the Study:

To explore novel ferroptosis-related therapeutic targets for LUAD.
To identify prognostic biomarkers for LUAD.
To investigate the role of SDCBP2 in LUAD progression and its association with ferroptosis.

Main Methods:

Utilized TCGA and GEO datasets to construct a ferroptosis risk model and identify LUAD hub genes.
Performed bioinformatics analysis, functional studies (in vitro), and assessed clinical samples to evaluate SDCBP2.
Employed multivariate Cox regression, ROC curve analysis, GSEA, GO/KEGG analysis, and gene knockdown experiments.

Main Results:

SDCBP2 was identified as a LUAD hub gene, overexpressed in malignant cells and an independent prognostic factor.
SDCBP2 expression demonstrated strong predictive power for LUAD patient prognosis.
Knockdown of SDCBP2 inhibited LUAD cell proliferation and migration, induced apoptosis, and altered ferroptosis markers (GSH, ROS).
A correlation between SDCBP2 and SLC7A11 expression was observed, associated with poorer prognosis.

Conclusions:

SDCBP2 promotes LUAD tumor progression.
SDCBP2 serves as a novel ferroptosis-related prognostic biomarker for LUAD.
Further investigation into the regulatory relationship between SDCBP2 and SLC7A11 is warranted.